Sequoia Vaccines, Inc. (SQVI)
| Market Cap | 78.50M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.49M |
| Shares Out | 8.72M |
| EPS (ttm) | -0.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About SQVI
Sequoia Vaccines is a clinical stage pharmaceutical company developing a vaccine designed to prevent recurrent urinary tract infections (UTIs) and small molecules for treating cancers and bacterial infections. Our lead clinical candidate, SEQ-400, is a vaccine under investigation for the prevention of recurrent UTIs, which received fast track designation by the Food and Drug Administration in December 2017. We are planning a UTI observation trial in 2023 which will seek to identify and define a population of patients with culture-verified recur... [Read more]
Financial Performance
Financial StatementsNews
Vaccine developer Sequoia Vaccines files for a $20 million IPO
Sequoia Vaccines, a Phase 1 biotech developing a vaccine for recurrent UTIs and small molecules for cancers, filed on Monday with the SEC to raise up to $20 million in an initial public offering.
Sequoia Vaccines IPO Registration Document (S-1)
Sequoia Vaccines has filed to go public with an IPO on the NYSE American.